Agenda

- US/State Data
- COVID Administration Guidance
- Vaccine Storage & Handling Updates
- Vaccine Ordering & Distribution
- OSIIS updates
- Questions/Suggestions
# DISTRIBUTION BY THE NUMBERS

<table>
<thead>
<tr>
<th>63 Weeks of Distribution</th>
<th>16.4 Million Pediatric Doses Administered</th>
</tr>
</thead>
<tbody>
<tr>
<td>687 Million Doses Delivered in U.S.</td>
<td>7.1 Million Children (5-11) Fully Vaccinated</td>
</tr>
<tr>
<td>550 Million Doses Administered</td>
<td>75% Adults 18+ Fully Vaccinated</td>
</tr>
<tr>
<td>215 Million Americans Fully Vaccinated</td>
<td>9.5% Wastage Reported</td>
</tr>
</tbody>
</table>
Statewide COVID-19 Vaccine Administration (as of 2/24/2022)

2,189,921 people have received at least 1 dose* of the COVID-19 vaccine

1,847,140 people are fully vaccinated** with the COVID-19 vaccine

735,325 people have received either a 3rd dose^ or booster dose^^ of the COVID-19 vaccine

Across Oklahoma, a total of 4,645,976 COVID-19 vaccine doses have been administered since 12/14/2020

*Refers to eligible individuals (ages 5 years+) receiving Pfizer and Moderna COVID-19 vaccines and/or receiving single shot of J&J/Janssen Vaccine; **Refers to eligible individuals (ages 5 years+) fully vaccinated after receiving either Pfizer and/or Moderna COVID-19 vaccines (both doses) and/or receiving single shot of J&J/Janssen Vaccine; ^3rd dose (Pfizer or Moderna) for individuals moderately to severely immunocompromised to be received at least 28 days after a second dose; ^^Booster dose for individuals 65+ or certain other adults at high risk of severe COVID-19 to be received at least six months after completion of the primary mRNA vaccine series or two months after receiving single dose of J&J/Janssen vaccine.

Note: Total vaccines administered does not include doses administered by federal entities (Bureau of Prisons, Veterans Health, Indian Health Service, or Department of Defense).

<table>
<thead>
<tr>
<th>Total Doses Delivered</th>
<th>Count</th>
<th>Adult Rate per 100K</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>6,967,830</td>
<td>231,895</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total Doses Administered</th>
<th>Count</th>
<th>Adult Rate per 100K</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5,713,651</td>
<td>175,018</td>
</tr>
</tbody>
</table>

At Least One Dose

- **2,767,253** people total (US – 76.3%)
  - **69.9%**
  - **74.8%**

- **2,766,970** people 5+ (US – 81.1%)
  - **81.1%**

- **2,695,882** people 12+ (US – 86.0%)
  - **84.0%**

- **2,524,795** people 18+ (US – 87.8%)
  - **95.0%**

- **673,303** people 65+ (US – 95.0%)
  - **59.8%**

Fully Vaccinated

- **2,214,720** people total (US – 64.8%)
  - **56.0%**
  - **59.8%**

- **2,214,671** people 5+ (US – 68.9%)
  - **65.0%**

- **2,160,952** people 12+ (US – 73.3%)
  - **67.2%**

- **2,020,246** people 18+ (US – 74.9%)
  - **85.5%**

- **542,809** people 65+ (US – 88.7%)
  - **49.8%**

Among the 735,325 people who received either a 3rd dose or booster dose, the majority are female.

Among the 735,325 people who received either a 3rd dose or booster dose, the ages ranged between 12-103 years.

Primary Race
- White: 74.0%
- Black: 5.5%
- Asian/Pacific Islander: 3.6%
- American Indian: 5.4%
- Other: 4.2%
- Unknown: 7.3%

Ethnicity
- Hispanic/Latino: 6.7%
- Not Hispanic/Latino: 81.2%
- Unknown: 12.1%

Note: 3rd dose (Pfizer or Moderna) for individuals moderately to severely immunocompromised to be received at least 28 days after a second dose. Booster dose for individuals 65+ or certain other adults at high risk of severe COVID-19 to be received at least six months after completion of the primary mRNA vaccine series or two months after receiving single dose of J&J/Janssen vaccine.

COVID Vaccine Administration Guidance

Anna Anthony, RN, BSN
Immunization Service, Public Health Nurse
• **Primary Series (12+)**
  - Two doses (0.3 mL) 3 weeks apart for 12 years of age and older.

• **Third Dose**
  - Single dose (0.3 mL) **at least** 28 days following the second dose for 12 years of age and older who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.
  - Single dose (0.2 mL) **at least** 28 days following the second dose for 5-11 years of age who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

• **Booster Dose**
  - A single Pfizer-BioNTech COVID-19 Vaccine booster dose (0.3 mL) may be administered intramuscularly at least 5 months after completing the primary series to individuals **12** years of age and older.
# COVID-19 Vaccination Schedule

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>0 month</th>
<th>1 month</th>
<th>2 month</th>
<th>3 month</th>
<th>4 month</th>
<th>5 month</th>
<th>6 month</th>
<th>7 month</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pfizer-BioNTech</strong> (ages 5–11 years)</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; dose† (3 weeks after 1&lt;sup&gt;st&lt;/sup&gt; dose)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pfizer-BioNTech</strong> (ages 12 years and older)</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; dose† (3-8 weeks after 1&lt;sup&gt;st&lt;/sup&gt; dose)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Booster dose‡ (at least 5 months after 2&lt;sup&gt;nd&lt;/sup&gt; dose)</td>
<td></td>
</tr>
<tr>
<td><strong>Moderna</strong> (ages 18 years and older)</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; dose† (4-8 weeks after 1&lt;sup&gt;st&lt;/sup&gt; dose)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Booster dose‡ (at least 5 months after 2&lt;sup&gt;nd&lt;/sup&gt; dose)</td>
</tr>
<tr>
<td><strong>Janssen</strong> (ages 18 years and older)</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose</td>
<td></td>
<td>Booster dose‡ (at least 2 months after 1&lt;sup&gt;st&lt;/sup&gt; dose)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*See [Guidance for COVID-19 vaccination for people who are moderately or severely immunocompromised](#) for schedule for people who are moderately or severely immunocompromised.

†An 8-week interval may be optimal for some people ages 12 years and older, especially for males ages 12 to 39 years. A shorter interval (3 weeks for Pfizer-BioNTech; 4 weeks for Moderna) between the first and second doses remains the recommended interval for: people who are moderately or severely immunocompromised; adults ages 65 years and older; and others who need rapid protection due to increased concern about community transmission or risk of severe disease.

‡An mRNA COVID-19 vaccine is preferred over the Janssen COVID-19 Vaccine for booster vaccination of people ages 18 years and older. For people ages 12–17 years, only Pfizer-BioNTech can be used. People ages 5–11 years should not receive a booster dose.
Pfizer Packaging and Dosage

• Three vaccine presentations are in circulation with different preparation and storage guidelines: Purple Cap, Gray Cap, and Orange Cap.

• Providers are encouraged to administer any Purple Cap vaccine in their inventory before Gray Cap.

• Children ages 5 through 11 years old should only be vaccinated with the Dilute Before Use Orange Cap vaccine formula (“Age 5y to <12y” on vial label).
  • It is critical to ensure children 5 through 11 years old only receive the Orange Cap vaccine in order to avoid potential age-related adverse events including product preparation issues, incorrect dose administered, and underdosage.

• All Pfizer vaccines are given based on age.
  • For example, patients who turn 12 between dose 1 and 2 will get 12+ formulation.

• See link provided for detailed information: Home | CVDvaccine-US.com
### Pfizer BioNTech COVID-19 Vaccine: Product Characteristics

<table>
<thead>
<tr>
<th>Description</th>
<th>Dilute Before Use</th>
<th>Do Not Dilute</th>
<th>Dilute Before Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age Group</td>
<td>12 years and older</td>
<td>12 years and older</td>
<td>5 through 11 years</td>
</tr>
<tr>
<td>Vial Cap Color and Label with Color Border</td>
<td>PURPLE</td>
<td>GRAY</td>
<td>ORANGE</td>
</tr>
<tr>
<td>Dose</td>
<td>30 mcg</td>
<td>30 mcg</td>
<td>10 mcg</td>
</tr>
<tr>
<td>Dose Volume</td>
<td>0.3 mL</td>
<td>0.3 mL</td>
<td>0.2 mL</td>
</tr>
<tr>
<td>Amount of Diluent* Needed per Vial</td>
<td>1.8 mL</td>
<td>NO DILUTION</td>
<td>1.3 mL</td>
</tr>
<tr>
<td>Doses per Vial</td>
<td>6 doses per vial</td>
<td>6 doses per vial</td>
<td>10 doses per vial (after dilution)</td>
</tr>
</tbody>
</table>

#### Storage Conditions

<table>
<thead>
<tr>
<th>Condition</th>
<th>Dilute Before Use</th>
<th>Do Not Dilute</th>
<th>Dilute Before Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>ULT Freezer (-90°C to -60°C)</td>
<td>9 months***</td>
<td>9 months***</td>
<td>9 months***</td>
</tr>
<tr>
<td>Freezer (-25°C to -15°C)</td>
<td>2 weeks</td>
<td>DO NOT STORE</td>
<td>DO NOT STORE</td>
</tr>
<tr>
<td>Refrigerator (2°C to 8°C)</td>
<td>1 month</td>
<td>10 weeks</td>
<td>10 weeks</td>
</tr>
<tr>
<td>Room Temperature (8°C to 25°C)</td>
<td>2 hours prior to dilution (including any thaw time)</td>
<td>12 hours prior to first puncture (including any thaw time)</td>
<td>12 hours prior to first puncture (including any thaw time)</td>
</tr>
<tr>
<td>After First Puncture (2°C to 25°C)</td>
<td>Discard after 6 hours</td>
<td>Discard after 12 hours</td>
<td>Discard after 12 hours</td>
</tr>
</tbody>
</table>

For more complete information and guidance, visit:  
• **Primary Series**
  • Two doses (0.5 mL each) 1 month apart.

• **3rd dose**
  • Single (0.5 mL) administered **at least** 28 days following the second dose is authorized for 18 years of age and older who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

• **Booster Dose**
  • Single dose (0.25 mL) **at least 5** months after completing the primary series for anyone 18+ years.
• **Primary Series**
  • One dose (0.5 mL each).

• **3rd dose**
  • No data supporting a 3rd dose of Johnson & Johnson/Janssen for immunocompromised persons.

• **Booster Dose**
  • Recommend that people receive an mRNA booster at 2 months after initial dose.

• **Changes to the J&J/Janssen EUA (as of January 2022)**
  • [https://www.fda.gov/media/146304/download](https://www.fda.gov/media/146304/download)
    • Pages 4-5, 13: Immune Thrombocytopenia

• **We are no longer receiving federal allocation of Janssen. All Janssen orders will be fulfilled by local County Health Departments.**
  • Providers need to remain aware of expiry date of vaccines in their inventory. Janssen will begin to expire in March and the majority will expire in April.
    • The expiration date can be obtained by entering the lot number from the carton or vial using the website [www.vaxcheck.jnj](http://www.vaxcheck.jnj)
## Mixing and Matching Boosters

<table>
<thead>
<tr>
<th>Who Should Get a Booster</th>
<th>When to Get a Booster</th>
<th>Which Booster can you get</th>
</tr>
</thead>
<tbody>
<tr>
<td>* Everyone 12+</td>
<td>* At least 5 months after completing your primary COVID 19 Vaccination Series</td>
<td><em>18+: any mRNA COVID vaccine</em></td>
</tr>
<tr>
<td>* Everyone 18+</td>
<td>* At least 5 months after completing your primary COVID 19 Vaccination Series</td>
<td><em>18+: any mRNA COVID vaccine</em></td>
</tr>
<tr>
<td>* Everyone 18+</td>
<td>* At least 2 months after completing your primary COVID 19 Vaccination Series</td>
<td><em>18+: any mRNA COVID vaccine</em></td>
</tr>
</tbody>
</table>

*12-17: PFIZER COVID Vaccine Only

*non-mRNA can be used to booster in special circumstances, please consult Primary Care Physician
Co-Administration

- You may administer COVID-19 and Influenza vaccines without regard to timing (both live, attenuated and non-live influenza vaccines).

- This includes administration of COVID-19 and Influenza vaccines on the same day, as well as co-administration at any time interval.

- Administer the COVID-19 vaccines and vaccines that may be more likely to cause a local reaction (i.e., adjuvanted influenza vaccines) in different limbs, if possible.

- When deciding whether to co-administer other vaccine(s) with COVID-19 vaccine, consider:
  - Whether the patient is behind or at risk of becoming behind on recommended vaccines
  - The patient's risk of vaccine-preventable disease
  - The reactogenicity profile of the vaccines
  - The likelihood of avoiding a missed opportunity to vaccinate
Vaccine Updates

• **SPIKEVAX**
  - trade name for MODERNA COVID-19 Vaccine
  - Biological Licensing Agreement (BLA) approved
  - Approved for 18+
  - Same Formulation as the EUA Moderna COVID-19 Vaccine
  - Interchangeable with EUA MODERNA COVID-19 Vaccine
  - Primary series of two doses, one month apart
  - Third Dose for Immunocompromised 18+
  - Booster for 18+

• **NOVAVAX**
  - Still in Phase 3 and Phase 4 trials in US
  - *Protein Based* Vaccine (not mRNA)
  - 90% effective
  - Israel has signed contract with NOVAVAX to produce 5 million doses
  - Future Plans:
    - FDA approval
      - Multi-Use Vials first rollout
    - Single Dose Vials in future rollouts
    - COVID-19/Flu Combo Vaccine
Vaccine Storage and Handling

Kaitlin Hixson, Immunization Field Consultant
Vaccine Expiration Dates

Important for all vaccines:
• Check the expiration dates upon receiving vaccines.
• Due to increased studies about stability data, check the expiration date again later (before administering vaccines and during weekly reconciliation).

How to check expiration dates?
• Scan QR code and it will take you to the website showing the expiration date
• Locate lot number on the package and type in the website
  • Janssen website
  • Moderna website
• Pfizer: printed on the box
Best Practice for Inventory Management

• What to do when a large amount of vaccine is nearing expiration.

• CDC Code Management Service
  • **Vaccine Lot Number and Expiration Date Webpage**
  • Click the "Register" button in the upper right-hand corner to complete the registration form to request access.

• Vaccine Expiration Date and Lookup & Reference Information:
  • **Expiry Information for Pfizer COVID-19 Vaccines**
  • **Moderna Vial Expiration Data Look Up Tool**
  • **J&J Expiration Date Look Up Tool**
Inventory Update Required
Vaccine Finder, OSIIS

Failure to maintain an updated inventory may impact vaccine orders.

- Will be listed by vaccine name and age designation.
  - Not by cap color.

- Training Videos and Guides:
  - https://www.vaccines.gov/covid-provider-resources/

- Step By Step Instructions:

- For assistance in updating Vaccine Finder or OSIIS please call Immunization Services at (405) 426-8580
The date printed on Orange Cap and Gray Cap Pfizer vaccine vials indicate the manufacture date and NOT the expiration date.

- The original expiration date was 6 months from the manufacturer date.
- The expiration date has now been extended to 9 months from the date of manufacture (while held at ULT frozen).

The OSIIS homepage displays a table displaying the current manufacturing dates with the 9-month extension.

If you have this vaccine in your inventory and it has been stored frozen (ULT), you will need to update the expiration date in OSIIS by selecting the Action button next to the vaccine in inventory > selecting Edit > and entering the new expiration date > and selecting Update.

Check the expiration date before administering or discarding the vaccine. If you see a wrong expiration date in OSIIS, please update it in OSIIS inventory and in your systems.
Pfizer Formulations

- Regardless of storage condition, Orange cap and gray cap vaccine vials should not be used after 9 months from the date of manufacture printed on the vial and cartons.
- The purple cap vaccine vials with an expiry date of September 2021-February 2022 (printed on the label) may remain in use for 3 months beyond the printed date if vials are maintained in approved storage conditions (-90°C to -60°C, -130°F to -76°F).

Updated Pfizer Data Logger: Controlant SAGA Logger

- Pfizer vaccine shippers are transitioning to an updated data logger from Controlant called "SAGA Logger."

- The SAGA Logger will provide improved performance for monitoring and reporting during shipment.

- The interactive LCD tracker display shows current temperatures and the minimum and maximum temperatures of the shipper contents during transit.

- The new SAGA Logger is slightly larger in size, and, as with the previous logger, requires return shipping in the packaging materials provided with your order.

- Key improvements to this device include:
  - Enhanced location accuracy with Wi-Fi.
  - Utilization of the 4G cellular network.
  - Interactive LCD display with an improved user interface.
  - 150 days of backup storage when no cloud is available.
  - Longer battery life.
  - Improved data transmission capability.
Wastage

Do not return unused, open, spoiled, or expired COVID19 vaccines to manufacturers, distributors, OSDH, or CHD. Store wasted vaccines separately from viable vaccines and label them accordingly. The label should say: “Wasted. DO NOT USE.”

Open vials must be disposed of in the sharps container at the end of each day. Do not put open vials back into the fridge: adjust in OSIIS and discard at the end of the day.

COVID-19 vaccine program requirements include reporting wastage (unused, open, spoiled, or expired) into OSIIS. Please follow the Wastage tip sheet to report COVID-19 vaccine wastage.

After recording, the vaccine must be disposed in accordance with Oklahoma regulations and processes to dispose of regulated medical waste.
Vaccine Ordering and Distribution

Sai Teja Paruchuri,
Vaccine Specialist
Reconciliation

Reconciliation – weekly

• Providers are required to reconcile and order covid vaccines during the ordering time frame: Tuesday through Monday.

• If a clinic doesn't reconcile COVID inventory for 14 days, they will not be able to create VFC & 317 vaccine orders.

• An informational video on COVID 19 vaccine reconciliation and ordering can be accessed at https://vimeo.com/528424790

• Inventory Reconciliation
Ordering Process: starting Aug 17
Minor change in delivery of orders with min quantities

- Providers **must reconcile their COVID-19 vaccines inventory weekly in OSIIS**
- Providers must create orders in OSIIS during the ordering timeframe which is **Tuesday through Monday**.
- If an order is placed in OSIIS sometime between Tuesday March 1st – Monday, March 7th, it will be processed and sent for fulfillment on Tuesday, March 8th.
- Providers can order as much as they need. If less than the minimum quantity is required, you still need to order the minimum quantity and add a comment in the Clinic Comments text area indicating the number of doses needed.
- For example, if you place an order for Pfizer 5-11 and Pfizer 12+ in the same order, and you wish to receive the minimum order quantity for Pfizer 12+ (100 doses) but only need 4 vials of Pfizer 5-11, please be sure to specify this information in the clinic comments.
Ordering Process

• The cut-off to create orders in OSIIS – Monday, 5pm.

• To make any changes or cancellations to orders after the deadline, providers must reach out ASAP.
  • To request a change, a provider should email to OSDH VaccineHelp <VaccineHelp@health.ok.gov>
  • If provider doesn’t receive a confirmation of changes/cancellation within 24h, provider must call
    the OSDH Immunization Service 405.426.8580 to ensure that the order has been cancelled.

• Orders with at least min quantity, will be approved in OSIIS and directly shipped to providers – subjected
  to CHANGE depending on the available weekly threshold amounts.

• Orders with less than min quantity will be rejected in OSIIS with a note that County Health Department
  (CHD) will fulfill the order and will get in touch with provider via email or phone.
  • Example of the message: "Your order will be fulfilled by your County Health Department. Watch for
e-mail communication about the process and phone calls to arrange vaccine transfer."
  • CHDs will deliver vaccines to providers on the same or the following week. Delivered by CHD
    employees, national guard, or courier service.
Ordering Process

• Upon delivery of the vaccine by CHD, provider should:
  1. Sign a Bill of Lading and keep a copy
  2. Check that delivered vaccines are viable
  3. Immediately place them into a storage according to the guidelines and label appropriately indicating expiration or/and Beyond-use dates (BUDs)
  4. **Accept transfer in OSIIS**

• Questions about orders:
  • OSIIS: OSIISHELP@health.ok.gov;
  • Vaccine ordering process: VaccineHelp@health.ok.gov;
  • Order fulfillment/delivery: contact CHDs (contacts will be shared in the follow-up email)
OSIIS Shot Records

Martin Lansdale, MPH
OSIIS Data Quality Coordinator
Moderna Booster in OSIIS

### Administer

<table>
<thead>
<tr>
<th>Vaccination Time</th>
<th>Administered By</th>
<th>Refusal Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>HH:MM AM/PM</td>
<td>TEST, TRAIN</td>
<td></td>
</tr>
</tbody>
</table>

**Vaccine**

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Mfg</th>
<th>Lot</th>
<th>Exp Date (MM/DD/YY)</th>
<th>Funding Src</th>
<th>Inv Loc</th>
<th>NDC</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19 mRNA (MOD)</td>
<td>I</td>
<td>MOD</td>
<td>TEST1</td>
<td></td>
<td></td>
<td></td>
<td>MODERNA</td>
</tr>
</tbody>
</table>

**Did not Admin**

- [ ]

**Delete**

- [ ]

**Body Site**

- [ ]

**Route**

- [ ]

**Dosage**

- [ ]

**Refusal Reason**

- [ ]

---

Oklahoma State Department of Health | COVID-19 Vaccine Provider Call
Pediatric Pfizer
Updating Passwords in OSIIS

Image of the OSIIS login page showing the option to change the password.
Shot Records: Public Portal

- OSIIS has a public portal that can be found at the below link:
  - [https://osiis.health.ok.gov/osiis_public/Application/PublicPortal](https://osiis.health.ok.gov/osiis_public/Application/PublicPortal)
  - **DISCLAIMER:** Not all shots are recorded in OSIIS as reporting private vaccine is not required.

- Patients can search and download a copy of their shot record for just covid shots or their complete immunization history through the portal.

- The public portal uses **patient name, date-of-birth, email, and phone number** for verification purposes (all have to be on the shot record in OSIIS or patients cannot pull their shot record).

- Currently OSIIS has a high amount of missing emails/phone numbers.

- Providers need to make sure to document email and phone number for the patient **and add/send it to OSIIS** with the shot record in order to increase the likelihood of a records match in the portal.
"How To" Guides

- Moderna Booster OSIIS Guide
- How to Turn On User Default Order Notifications
- Inventory Reconciliation
- How to Place a Covid-19 Vaccine Order
- Immunizing a Patient for COVID
- How to add an extra dose
- Wastage
Questions/Suggestions
Personal Protective Equipment (PPE):
  • https://okppe.mybigcommerce.com/
  • Proceed to the "Need an Account?" page and complete the Contact Us for an account.

Testing:
  • Nasopharyngeal, throat, saliva
  • Testing@health.ok.gov

Monoclonal Antibodies:
  • Antivirals@health.ok.gov
  • https://oklahoma.gov/covid19/what-you-should-know/monoclonal-antibody-therapies.html
• So will each CHD start ordering the COVID vaccine through OSIIS and not through a designated person?
  • The process has not changed, all providers place COVID Vaccine orders through OSIIS. If your facility has a designated COVID ordering contact, continue placing orders through this contact.

• How long do we keep expired vaccine at our CHD before we can dispose of them?
  • There is no defined timeline, but the sooner you dispose of expired vaccine, the chances of administering expired vaccine is greatly reduced.

• Where can I find the presentation slides and recording?
  • https://oklahoma.gov/covid19/providers/vaccine-provider-calls.html